108.35
price down icon0.54%   -0.74
 
loading
前日終値:
$109.09
開ける:
$108.59
24時間の取引高:
82,471
Relative Volume:
0.01
時価総額:
$134.67B
収益:
$28.73B
当期純損益:
$5.97B
株価収益率:
22.81
EPS:
4.75
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
+1.65%
1か月 パフォーマンス:
+4.12%
6か月 パフォーマンス:
+17.20%
1年 パフォーマンス:
+70.87%
1日の値動き範囲:
Value
$108.12
$108.79
1週間の範囲:
Value
$105.58
$109.55
52週間の値動き範囲:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
名前
Gilead Sciences Inc
Name
セクター
Healthcare (1172)
Name
電話
(650) 574-3000
Name
住所
333 LAKESIDE DR, FOSTER CITY, CA
Name
職員
17,600
Name
Twitter
@GileadSciences
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
GILD's Discussions on Twitter

GILD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
108.26 134.00B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
721.00 650.81B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.86 368.56B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
183.79 321.13B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
111.57 222.75B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.75 303.04B 43.59B 15.04B 10.74B 3.3766

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-03-04 繰り返されました Oppenheimer Outperform
2025-02-18 アップグレード Deutsche Bank Hold → Buy
2025-02-13 アップグレード DZ Bank Hold → Buy
2025-01-10 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Buy
2024-11-08 ダウングレード Maxim Group Buy → Hold
2024-10-21 アップグレード Leerink Partners Market Perform → Outperform
2024-10-17 開始されました Bernstein Outperform
2024-10-07 アップグレード Wells Fargo Equal Weight → Overweight
2024-07-08 アップグレード Raymond James Mkt Perform → Outperform
2024-05-01 繰り返されました Maxim Group Buy
2024-04-24 アップグレード HSBC Securities Reduce → Hold
2024-02-22 ダウングレード Truist Buy → Hold
2023-11-09 開始されました Deutsche Bank Hold
2023-09-08 アップグレード BofA Securities Neutral → Buy
2023-09-06 開始されました HSBC Securities Reduce
2023-07-24 繰り返されました Barclays Equal Weight
2023-05-16 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-28 再開されました Piper Sandler Overweight
2023-01-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-12-13 再開されました BofA Securities Neutral
2022-12-09 ダウングレード DZ Bank Buy → Hold
2022-10-31 アップグレード Barclays Underweight → Equal Weight
2022-10-28 繰り返されました BMO Capital Markets Market Perform
2022-10-28 繰り返されました Cowen Outperform
2022-10-28 繰り返されました JP Morgan Overweight
2022-10-28 繰り返されました Jefferies Buy
2022-10-28 アップグレード Piper Sandler Neutral → Overweight
2022-10-28 繰り返されました RBC Capital Mkts Outperform
2022-10-28 アップグレード Truist Hold → Buy
2022-10-28 繰り返されました Wells Fargo Equal Weight
2022-10-04 アップグレード JP Morgan Neutral → Overweight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-28 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-02 繰り返されました BMO Capital Markets Outperform
2022-02-02 繰り返されました BofA Securities Neutral
2022-02-02 繰り返されました RBC Capital Mkts Outperform
2022-02-02 繰り返されました Truist Hold
2022-02-02 繰り返されました Wells Fargo Equal Weight
2022-01-28 アップグレード Argus Hold → Buy
2022-01-06 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 アップグレード BMO Capital Markets Market Perform → Outperform
2021-11-19 再開されました Piper Sandler Neutral
2021-10-20 再開されました Cowen Outperform
2021-07-30 繰り返されました BMO Capital Markets Market Perform
2021-07-30 繰り返されました RBC Capital Mkts Outperform
2021-04-01 アップグレード Bernstein Mkt Perform → Outperform
2021-03-30 アップグレード Redburn Neutral → Buy
2021-01-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-11-03 再開されました Morgan Stanley Equal-Weight
2020-10-28 開始されました UBS Neutral
2020-09-30 再開されました Jefferies Buy
2020-09-15 アップグレード Maxim Group Hold → Buy
2020-07-31 繰り返されました Credit Suisse Neutral
2020-07-31 繰り返されました Morgan Stanley Equal-Weight
2020-07-31 繰り返されました Piper Sandler Overweight
2020-07-31 繰り返されました RBC Capital Mkts Outperform
2020-07-31 繰り返されました SunTrust Hold
2020-07-31 繰り返されました Wells Fargo Equal Weight
2020-07-20 アップグレード Credit Suisse Underperform → Neutral
2020-06-03 アップグレード SVB Leerink Mkt Perform → Outperform
2020-05-26 アップグレード SunTrust Sell → Hold
2020-05-01 ダウングレード JP Morgan Overweight → Neutral
2020-05-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-01 ダウングレード SunTrust Hold → Sell
2020-04-27 ダウングレード UBS Buy → Neutral
2020-04-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-04-20 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-17 ダウングレード CFRA Hold → Sell
すべてを表示

Gilead Sciences Inc (GILD) 最新ニュース

pulisher
May 28, 2025

Gilead Sciences and Kite Pharma To Announce Transformative - CSRwire

May 28, 2025
pulisher
May 27, 2025

Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria

May 27, 2025
pulisher
May 26, 2025

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com

May 26, 2025
pulisher
May 26, 2025

Gilead Ready To Go After Hepatitis D Again - insights.citeline.com

May 26, 2025
pulisher
May 26, 2025

Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha

May 26, 2025
pulisher
May 26, 2025

GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena

May 26, 2025
pulisher
May 25, 2025

Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN

May 25, 2025
pulisher
May 24, 2025

Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter

May 24, 2025
pulisher
May 24, 2025

Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance

May 24, 2025
pulisher
May 23, 2025

Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer - simplywall.st

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences (GILD) Achieves Key Trial Milestone with Trodelv - GuruFocus

May 23, 2025
pulisher
May 23, 2025

After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial - Fierce Pharma

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) Announces Promising Results from Trodelvy Study | - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Gilead posts trial win for Trodelvy in breast cancer (GILD) - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Gilead (GILD) Announces Promising Results from Trodelvy Study | GILD Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

ASCENT-03Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study - StreetInsider

May 23, 2025
pulisher
May 23, 2025

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire

May 23, 2025
pulisher
May 23, 2025

Gilead records another pivotal study success for Trodelvy in first-line TNBC - FirstWord Pharma

May 23, 2025
pulisher
May 22, 2025

Sector Update: Health Care Stocks Softer Late Afternoon - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Sector Update: Health Care Stocks Retreat Thursday Afternoon - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gilead (GILD) Experiences Significant Increase in Bearish Options Activity | GILD Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gilead Sciences to Acquire HOOKIPA Pharma Assets for $10M - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha

May 22, 2025
pulisher
May 22, 2025

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs - Fierce Biotech

May 22, 2025
pulisher
May 22, 2025

Hookipa Pharma Sells Assets to Gilead Sciences - TipRanks

May 22, 2025
pulisher
May 21, 2025

What Analysts Are Saying About Gilead Sciences Stock - Benzinga

May 21, 2025
pulisher
May 21, 2025

Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - CSRwire

May 21, 2025
pulisher
May 21, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Gilead Sciences (GILD) Receives Hold Rating from Needham | GILD Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now? - Zacks Investment Research

May 20, 2025
pulisher
May 20, 2025

Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 10 - 3BL Media

May 20, 2025
pulisher
May 19, 2025

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

May 19, 2025
pulisher
May 19, 2025

Unusual Options Alert: The Smart Money Is Piling Into Gilead Sciences (GILD) - Barchart.com

May 19, 2025
pulisher
May 19, 2025

Gilead Sciences: Buy Rating Affirmed Amid Promising Lenacapavir Approval and Market Expansion - TipRanks

May 19, 2025
pulisher
May 19, 2025

Gilead Sciences discovers new PRMT5 inhibitors - BioWorld MedTech

May 19, 2025
pulisher
May 18, 2025

Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance

May 18, 2025
pulisher
May 16, 2025

Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Gilead Sciences (GILD) is Flashing a Quant Signal That Wall Street is Ignoring - Money Morning

May 16, 2025
pulisher
May 16, 2025

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories - CSRwire

May 16, 2025
pulisher
May 16, 2025

Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and E - BioSpace

May 15, 2025
pulisher
May 15, 2025

Does Gilead's drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals

May 15, 2025
pulisher
May 15, 2025

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Gilead And Kite Announce Presentation Of Transformative Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Does Gilead's latest PreP drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals

May 15, 2025
pulisher
May 15, 2025

Upcoming Meeting for GILD in Foster City | GILD Stock News - GuruFocus

May 15, 2025

Gilead Sciences Inc (GILD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Gilead Sciences Inc (GILD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Mercier Johanna
Chief Commercial Officer
May 22 '25
Sale
107.52
28,000
3,010,564
121,152
drug_manufacturers_general PFE
$23.18
price down icon 1.82%
$278.78
price down icon 0.34%
drug_manufacturers_general GSK
$39.30
price down icon 0.48%
drug_manufacturers_general MRK
$76.17
price down icon 1.83%
drug_manufacturers_general NVO
$68.60
price down icon 2.61%
大文字化:     |  ボリューム (24 時間):